This table shows how much of what BC has ordered, both of vaccines which have been approved and those for which the orders are more ah theoretical.
|Manufacturer (type, effectiveness)||# People||# BC People||Status||Expected EUA*|
|Pfizer (mRNA, 95%)||20M-38M||2.5-4.75M||Approved||2020-12-09|
|Moderna (mRNA, 94.5%)||22M||2.75M||Approved||2020-12-23|
|AstraZeneca / Oxford (DNA, 62%)||10M||1.25M||Approved||2021-02-26|
|Serum Institute of India / COVISHIELD |
|J&J/Janssen (DNA, 57-72%, one-shot)||10M–38M||1.25-4.75M||Approved||2021-03-05|
|COVAX, (Pfizer, AZ, J&J, Novavax, Sanofi)||7.5Mish||~1.85M||Some approved|||
|Novavax (protein, 96.4%/48.6% SA)||26M–38M||3.25M-4.75M||2020-11-28 Interim results||2021-04-03 |
|Medicago (tobacco, ?)||10M–38M||1.25-4.75M||Ph3 expected to start late Jan 2021||2021-07-01|
|Sanofi/GSK (mRNA, ?)||26M–36M||3,25M-4.5M||delayed to Feb 2021?||2021-Q4?|
|Providence Therapeutics (mRNA)||Started P1 trials 2021-01-26||2021-08-01?|
Note that I say “people”, not doses, to cope with the vaccines having different numbers of doses per person. Janssen uses one dose, while all the others are two doses per person.
* EUA = “Emergency Use Authorization”, a faster approval process than is normal for vaccines.
 Serum Institute of India manufactures the AstraZeneca under sublicense, under the name COVISHIELD, in association with Verity Pharmaceuticals Canada Inc.
 COVAX is a buyer’s coop, led by the World Health Organization, with a lot of different vaccines. Alas, I have not yet found an authoritative list of which vaccines it has. Canada has a contract to get 15M doses through COVAX, but it is not clear how much of which specific vaccines, which means I can’t say exactly how many people that will vaccinate.
 In an article dated 2 March 2021, Novavax says they want to finish the UK/SA trial, which they will do mid-March, before submitting. That’s strange, though, because in a press release dated 24 January 2021, they crowed about how they have Phase 3 results. However, on 12 March 2021, they declared Ph3 over. So I don’t understand what the 24 Jan press release was about.